FDA Cites Fagron BV in 2026-05-12 Warning Letter — Compounding Pharmacy/Adulterated Drug Products
Letter issued · posted to fda.gov .
Subject as published: Compounding Pharmacy/Adulterated Drug Products
TL;DR
Here's the summary: FDA issued a Warning Letter to Fagron BV on 2026-05-12 citing: Compounding Pharmacy/Adulterated Drug Products. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-bv-724551-05122026
Argus analysis
Fagron BV (MARCS-CMS 724551) received an FDA Warning Letter dated May 12, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: Compounding Pharmacy/Adulterated Drug Products. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 9, 2026.
Compounding letters typically cite section 503A (traditional compounding) or 503B (outsourcing facilities) of the FD&C Act, frequently combined with CGMP or insanitary-conditions findings. FDA distinguishes compounders from manufacturers largely on production scale and patient-specific prescriptions — a distinction these letters often argue the firm has exceeded.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same compounding pharmacy category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Compounding letters typically cite Section 503A (FDCA) for traditional compounders or Section 503B for outsourcing facilities, frequently combined with insanitary-conditions findings.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Fagron BV MARCS-CMS 724551 — May 12, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT Product: Drugs Recipient: Recipient Name Rafael Padilla Recipient Title CEO Fagron BV Fascinatio Boulevard 350 3065 WB Rotterdam Netherlands Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER WL # 724551 May 12, 2026 Dear Mr. Padilla: You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b] 1 on April 21, 2017, and most recently on November 22, 2025. From October 9, 2025, to November 5, 2025, FDA investigators inspected your facility, Fresenius Kabi Compounding, LLC dba Fagron Sterile Services, located at 20 Dan Rd, Canton, MA 02021. During the inspection, investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk. FDA issued a Form FDA 483 to your facility on November 5, 2025. FDA reviewed your facility’s responses, dated November 26, 2025, December 1, 2025, and December 5, 2025, and acknowledge receipt of your subsequent correspondence. FDA further acknowledges that your firm initiated a voluntary recall on February 5, 2026, of various lots of drug products, within expiry, produced using (b)(4) IV Bags intended or expected to be sterile due to lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA. A. Compounded Drug Products under the FDCA Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met. 2 An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Fagron BV publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fagron-bv-724551-05122026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Compounding (503A) warning letter?
- Compounding letters typically cite Section 503A (FDCA) for traditional compounders or Section 503B for outsourcing facilities, frequently combined with insanitary-conditions findings.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Fagron BV in 2026-05-12 Warning Letter — Compounding Pharmacy/Adulterated Drug Products. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-fagron-bv-2026-05-12-compounding
"FDA Cites Fagron BV in 2026-05-12 Warning Letter — Compounding Pharmacy/Adulterated Drug Products." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-fagron-bv-2026-05-12-compounding.
Argus HQ Research. "FDA Cites Fagron BV in 2026-05-12 Warning Letter — Compounding Pharmacy/Adulterated Drug Products." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-fagron-bv-2026-05-12-compounding.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_fagron_bv_2026_05_12_compounding_2026,
title = {FDA Cites Fagron BV in 2026-05-12 Warning Letter — Compounding Pharmacy/Adulterated Drug Products},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-fagron-bv-2026-05-12-compounding},
note = {Accessed: July 13, 2026}
}